WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ELVN earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$71.6M
Current Profit Margin
0%

ELVN Return on Equity

Current Company
-26.6%
Current Industry
-63.5%
Current Market
188%
ELVN's Return on Equity (-26.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ELVN announces earnings.

ELVN Return on Assets

Current Company
-25.2%
Current Industry
2.9%
ELVN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ELVN Return on Capital Employed

Current Company
-29.1%
Current Industry
19.5%
ELVN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ELVN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ELVN$0.00-$70.98M-$71.58MN/AN/A
LBPH$0.00-$54.42M-$54.42MN/AN/A
AUPH$175.51M-$63.05M-$78.02M+227.90%N/A
PLRX$1.58M-$155.84M-$161.34M-59.21%N/A
ARCT$166.80M-$41.52M-$29.73M+60.31%N/A
View Top Biotech Stocks

ELVN earnings dates

Next earnings date
Jun 21, 2024

Enliven Therapeutics Earnings & Revenue FAQ

What were ELVN's earnings last quarter?

On Invalid Date, Enliven Therapeutics (NASDAQ: ELVN) reported Q4 2023 earnings per share (EPS) of -$0.46, up 84.14% year over year. Total Enliven Therapeutics earnings for the quarter were -$19.37 million. In the same quarter last year, Enliven Therapeutics's earnings per share (EPS) was -$2.90.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.

What was ELVN's earnings growth in the past year?

As of Q2 2024, Enliven Therapeutics's earnings has grown year over year. Enliven Therapeutics's earnings in the past year totalled -$71.58 million.

What is ELVN's earnings date?

Enliven Therapeutics's earnings date is Invalid Date. Add ELVN to your watchlist to be reminded of ELVN's next earnings announcement.

What was ELVN's revenue last quarter?

On Invalid Date, Enliven Therapeutics (NASDAQ: ELVN) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Enliven Therapeutics's revenue was $0.00.

What was ELVN's revenue growth in the past year?

As of Q2 2024, Enliven Therapeutics's revenue has grown null year over year. Enliven Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.